Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Daniel Anthony, Professor of Experimental Neuropathology in the Department of Pharmacology, is the scientific lead in a joint research team running a new clinical trial to evaluate the effectiveness for the treatment of COVID-19 of Nafamostat. This existing medicine, manufactured by Nichi-Iko Pharmaceutical Co Ltd, is a well-established treatment in Japan for pancreatitis. The company has generously donated supplies of Nafamostat for the initial clinical evaluation.

The clinical trial is being undertaken at the University of Edinburgh. The trial will build on evidence that has previously shown that Nafamostat can prevent the virus from infecting human cells in the laboratory. Studies have shown that the drug blocks virus entry into lung cells and prevents it from multiplying in the human body. In this way the research team hope it could reduce the severity of disease in infected individuals.

“Our primary objective will be to discover whether treatment with Nafamostat, a serine protease inhibitor, is able to prevent clinical progression of the infection, reduce mortality, and speed recovery of patients,” said Professor Anthony.   

This study is being supported by a grant from the medical research charity LifeArc as part of its activity to address the need for new therapies for COVID-19.

Organisation of the trial has been led by not-for-profit company Latus Therapeutics, founded by Dr Bobojon Nazarov. Dr Nazarov holds an MSc in Pharmacology, a DPhil in Chemical Biology and an MBA from the University of Oxford.

Other members of the research team include Professor Graham Richards, former Head of Chemistry at Oxford and founder of Oxford University Innovation; Professor Paul Finn, CEO of Oxford Drug Design; Dr Colin Ferrett and Dr Suzie Anthony from Oxford University Hospitals NHS Trust; and Dr Emma Ladds from the Nuffield Department of Primary Care Health Sciences at Oxford.

Similar stories

International collaboration by Potter group uncovers vital element in regulation of Na⁺/K⁺- ATPase-α1

Department

An international collaboration of the Potter Group with Solomon Snyder’s Group in the USA and with Chinese and German colleagues has uncovered the myo-inositol polyphosphate pyrophosphate 5-InsP7 as a regulator of the Na⁺/K⁺- ATPase-α1

Professor Angela Russell receives 2021 Harrington UK Rare Disease Scholar Award

Department Russell Group

Angela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).

Professor Fran Platt appointed as new Head of Department of Pharmacology

Department

Professor Fran Platt has been appointed as the new Head of Department for Pharmacology at the University of Oxford. Fran took up her new post with effect from 1 June 2020 and will serve for an initial period of five years.

The Department mourns the loss of three greats in neuropharmacology

Department

This summer three of the world’s most distinguished neurochemists died; each was a member of the Department during their outstanding scientific careers.

Professor Fran Platt secures £1M funding over two years for vital Parkinson's Disease research, in collaboration with Pfizer

Department

There is an increasing body of genetic and biochemical evidence that points toward lysosomal dysfunction as a risk factor for developing age-related neurodegenerative disorders, including Parkinson’s disease (PD).

New Galione group paper explores the role for early Ca2+ signals in phagocytosis

Department

The Galione Lab has a paper published in The EMBO Journal showing that local Ca2+‐nanodomains formed by two‐pore channels (TPCs) on endo-lysosomes are shown to drive phagocytosis in macrophages. Moreover, different endo-lysosomal Ca2+ channels do different jobs at phagocytosis (extreme compartmentation).